Alan D. Widgerow, MBBCh, MMed, FCS, FACS

Alan D Widgerow – MBBCh; MMed ; FCS; FACS
Chief Scientific Officer Galderma
Head, Skin Science Institute of Innovation
Head, Alastin and Dermatological Skincare Innovations

Alan Widgerow is a plastic surgeon who ran a solo private practice in South Africa for over 20 years. He has held various positions in numerous academic and professional associations, including that of President of the Association of Plastic and Reconstructive Surgery of Southern Africa (APRSSA). He is the author of over 220 plastic surgery-related publications and 2 books. He was also the founder and medical director of 13 wound clinics in South Africa. Prof. Widgerow relocated to Irvine, California, in Dec 2009 to pursue his interests in medical device innovations, cosmeceuticals, and wound care, but he still plays an active role in academic medicine worldwide. In 2012, he was appointed to the faculty of the University of California, Irvine, Plastic Surgery Department as a Full Adjunct Professor and Director of the Center for Tissue Engineering, and in 2021, he was appointed as its Division Chief of Research. He is involved in multiple projects related to adipose-derived stem cells, adipose decellularized matrix, wound healing, and transplantation. In 2018, he was awarded the Distinguished Faculty Mentor of the Year Award by the Institute for Clinical and Translational Science, UCI, and in 2025, he received the Outstanding Volunteer Faculty of the Year for Excellence in Teaching and Educating Residents by UCI Plastic Surgery.
Dr. Widgerow has developed and licensed multiple products in the US and South African markets. In 2015, he joined ALASTIN Skincare, Inc., an early-stage startup professional skincare company, as their Chief Medical Officer. Over the past 10 years, he has led the scientific innovations team in introducing multiple new products based on novel wound healing pathways. The resulting products have been validated through gene expression studies, in vitro testing, biopsies, and multiple clinical trials, resulting in a range of products. that have surpassed previous scientific validations in this space. He continues to pursue patented novel concepts, peptide technologies and vigorous testing thus contributing to Alastin Skincare’s position as the fastest growing professional skin care company in the US for many years. In 2021 Alastin Skincare was acquired by Galderma and in June 2022 Dr Widgerow was appointed Chief Scientific Officer of Galderma and in 2025 was appointed Head of Dermatological skincare Innovation for Galderma where he is involved in Ax, Rx and Cx product science research and development.